Lifecome Biochemistry Co.,Ltd.'s (SZSE:002868) 26% Gain Last Week Benefited Both Private Companies Who Own 43% as Well as Insiders
Lifecome Biochemistry Co.,Ltd.'s (SZSE:002868) 26% Gain Last Week Benefited Both Private Companies Who Own 43% as Well as Insiders
Key Insights
关键见解
- Significant control over Lifecome BiochemistryLtd by private companies implies that the general public has more power to influence management and governance-related decisions
- 51% of the business is held by the top 3 shareholders
- 33% of Lifecome BiochemistryLtd is held by insiders
- 私营公司对Lifecome BioChemistryLtd的严格控制意味着公众拥有更大的影响管理和治理相关决策的权力
- 51% 的业务由前三名股东持有
- Lifecome BioChemistryLtd33%的股份由内部人士持有
If you want to know who really controls Lifecome Biochemistry Co.,Ltd. (SZSE:002868), then you'll have to look at the makeup of its share registry. We can see that private companies own the lion's share in the company with 43% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
如果你想知道谁真正控制了Lifecome Bijecume Co., Ltd.(深圳证券交易所:002868),那么你必须看看其股票登记处的构成。我们可以看到,私营公司拥有该公司的大部分股份,所有权为43%。换句话说,该集团面临最大的上行潜力(或下行风险)。
While private companies were the group that reaped the most benefits after last week's 26% price gain, insiders also received a 33% cut.
尽管在上周股价上涨26%之后,私营公司是获得最大收益的群体,但内部人士也获得了33%的下调。
In the chart below, we zoom in on the different ownership groups of Lifecome BiochemistryLtd.
在下图中,我们放大了Lifecome BiochemistryLtd的不同所有权群体。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240224/0-b6821611dd84aa24c93ee66ed9ee7218-0-a70063c5c3f5fe1bfe09f6460b403dfc.png/big)
What Does The Lack Of Institutional Ownership Tell Us About Lifecome BiochemistryLtd?
关于Lifecome BiochemistryLtd,缺乏机构所有权告诉我们什么?
Institutional investors often avoid companies that are too small, too illiquid or too risky for their tastes. But it's unusual to see larger companies without any institutional investors.
机构投资者通常会避开规模太小、流动性太差或风险太大的公司,不符合他们的口味。但是,看到没有任何机构投资者的大型公司是不寻常的。
There could be various reasons why no institutions own shares in a company. Typically, small, newly listed companies don't attract much attention from fund managers, because it would not be possible for large fund managers to build a meaningful position in the company. On the other hand, it's always possible that professional investors are avoiding a company because they don't think it's the best place for their money. Lifecome BiochemistryLtd might not have the sort of past performance institutions are looking for, or perhaps they simply have not studied the business closely.
没有机构拥有公司股份的原因可能多种多样。通常,小型的新上市公司不会引起基金经理的太多关注,因为大型基金经理不可能在公司中建立有意义的地位。另一方面,专业投资者总是有可能避开一家公司,因为他们认为这不是赚钱的最佳去处。Lifecome BioChemistryLtd可能没有机构想要的那种过去的业绩,或者他们可能根本没有仔细研究该业务。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240224/0-b6821611dd84aa24c93ee66ed9ee7218-1-ac759866c819ffb30b24d9d3e98134a6.png/big)
Hedge funds don't have many shares in Lifecome BiochemistryLtd. The company's largest shareholder is Tan Ping Lai, with ownership of 31%. The second and third largest shareholders are Shangrao Changxin No. 2 Enterprise Management Center (Limited Partnership) and Hangzhou Yirui Investment Partnership Enterprise (Limited Partnership), with an equal amount of shares to their name at 10%. In addition, we found that Tanping Lai, the CEO has 1.0% of the shares allocated to their name.
对冲基金在Lifecome BioChemistryLtd的股份不多。该公司的最大股东是陈平来,所有权为31%。第二和第三大股东是上饶长信二号企业管理中心(有限合伙)和杭州易瑞投资合伙企业(有限合伙企业),其名下股份数量相等,为10%。此外,我们发现首席执行官赖坦平拥有1.0%的股份以他们的名义分配。
After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
在进一步挖掘之后,我们发现前三名股东共同控制了公司一半以上的股份,这意味着他们拥有影响公司决策的巨大权力。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
研究机构所有权是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪也可以达到同样的目的。我们的信息表明,分析师对该股没有任何报道,因此可能鲜为人知。
Insider Ownership Of Lifecome BiochemistryLtd
Lifecome BiochemistryLtd 的内部
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。管理层最终对董事会负责。但是,经理成为执行委员会成员的情况并不少见,尤其是当他们是创始人或首席执行官时。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多数人认为内部所有权是积极的,因为这可能表明董事会与其他股东关系良好。但是,在某些情况下,过多的权力集中在该群体中。
Our information suggests that insiders maintain a significant holding in Lifecome Biochemistry Co.,Ltd.. Insiders own CN¥976m worth of shares in the CN¥3.0b company. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.
我们的信息表明,内部人士持有Lifecome生物化学公司的大量股份。,有限公司。内部人士拥有这家30亿元人民币公司价值9.76亿元人民币的股份。我们可以说这表明了与股东的一致性,但值得注意的是,该公司仍然很小;一些内部人士可能已经创立了该公司。你可以点击这里查看这些内部人士是否在买入或卖出。
General Public Ownership
一般公有制
The general public, who are usually individual investors, hold a 22% stake in Lifecome BiochemistryLtd. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
公众通常是个人投资者,持有Lifecome BioChemistryLtd22%的股份。尽管这种所有权规模可能不足以影响对他们有利的政策决定,但它们仍然可以对公司政策产生集体影响。
Private Company Ownership
私人公司所有权
We can see that Private Companies own 43%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
我们可以看到,私人公司拥有已发行股份的43%。私营公司可能是关联方。有时,内部人士通过持有私营公司而不是以个人身份对上市公司感兴趣。虽然很难得出任何粗略的结论,但值得注意的是,这是一个需要进一步研究的领域。
Next Steps:
后续步骤:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Lifecome BiochemistryLtd , and understanding them should be part of your investment process.
我觉得看看究竟谁拥有一家公司非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,投资风险的幽灵无处不在。我们已经向Lifecome BioChemistryLtd确定了三个警告信号,了解它们应该是您投资过程的一部分。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。